The decrease of paclitaxel efflux by pretreatment of interferon-γ and tumor necrosis factor-α after intracerebral...

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Paclitaxel is effective against many cancers but shows limited efficacy against malignant glioma.
• P-glycoprotein (P-gp) at the blood-brain barrier (BBB) may restrict paclitaxel's brain penetration.
• Understanding P-gp mediated transport is crucial for optimizing brain tumor treatments.

Purpose of the Study:

• To investigate the role of P-gp in paclitaxel efflux across the BBB.
• To determine if inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) modulate P-gp function.

Main Methods:

• Utilized the brain efflux index method in rats to quantify paclitaxel transport across the BBB.
• Assessed the effect of unlabeled paclitaxel and verapamil on [(3)H]paclitaxel elimination.
• Examined the impact of pre-treatment with TNF-α and IFN-γ on paclitaxel efflux.

Main Results:

• Paclitaxel is actively transported out of the rat brain via a P-gp mediated process.
• The efflux rate of [(3)H]paclitaxel was determined to be 1.87×10(-2)±0.16×10(-2)min(-1).
• TNF-α and IFN-γ significantly reduced paclitaxel efflux from the brain, indicating decreased P-gp activity.

Conclusions:

• P-gp plays a significant role in limiting paclitaxel distribution within the central nervous system.
• Neurological conditions involving TNF-α and IFN-γ may alter P-gp efflux function.
• Modulating P-gp activity could be a strategy to enhance the efficacy of paclitaxel and similar drugs in treating brain malignancies.